Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma

Baoyu He, Hongli Pan, Fengque Zheng, Saiqiong Chen, Qingli Bie, Jinghe Cao, Rou Zhao, Jing Liang, Li Wei, Jianchao Zeng, Hui Li, Xing Cui, Yixuan Ding, Chao Wei, Tiantian Xiang, Yuhe Cheng, Gui Qiu, Shishun Huang, Li-Bo Tang, Jiansheng Chang, Delan Luo, Jie Yang, Bin ZhangJournal of Experimental & Clinical Cancer Research 2022 · DOI

TL;DR

Researchers have identified a novel long noncoding RNA, LINC00930, that acts as a metabolic master switch in nasopharyngeal carcinoma (NPC). By functioning as a molecular scaffold that epigenetically activates the glycolytic enzyme PFKFB3, this lncRNA fuels tumor growth and offers a potent new target for sensitizing cancer cells to radiotherapy.

What Problem Does This Paper Address?

Nasopharyngeal carcinoma (NPC) is a head and neck cancer with a particularly high incidence in Southeast Asia. While radiotherapy is the standard treatment, many patients suffer from treatment failure due to rapid tumor cell proliferation and metastasis.

A hallmark of these aggressive cancer cells is the Warburg effect—a metabolic reprogramming where cells favor glycolysis over more efficient pathways to generate energy and building blocks for rapid division. While we know enzymes drive this process, the "conductors" behind the scenes—specifically long noncoding RNAs (lncRNAs)—remain poorly understood. This paper investigates which lncRNAs drive NPC metabolism and how they might be targeted to improve clinical outcomes.

Methods

The authors employed a multi-layered approach to bridge the gap between bioinformatics and clinical application:

  • Screening: They performed a meta-analysis of RNA-seq data followed by a high-throughput siRNA screen of 50 candidate lncRNAs to identify those that simultaneously affected cell viability and lactate production.
  • Metabolic Profiling: Using Seahorse XF96 analyzers and $^{13}$C-labeled glucose metabolic flux analysis, they quantified how LINC00930 alters the "fuel consumption" of cancer cells.
  • Mechanistic Mapping: To find out how a non-coding RNA controls genes, they used RNA pull-down followed by Mass Spectrometry to identify protein partners, and ChIRP (Chromatin Isolation by RNA Purification) to see exactly where the lncRNA sits on the genome.
  • In Vivo Models: They validated their findings using both Cell-Derived Xenografts (CDX) and Patient-Derived Xenografts (PDX), which are considered the "gold standard" for mimicking human tumor responses in mice.

Datasets

The study utilized several high-profile transcriptomic datasets:

  • Public Repositories: Microarray and RNA-seq data from GEO (GSE64634, GSE12452, GSE118719, GSE40290) and The Cancer Genome Atlas (TCGA-HNSC).
  • Internal Patient Cohorts: Two distinct internal cohorts consisting of 71 fresh-frozen tissues and 128 paraffin-embedded NPC samples, along with 120 nasopharyngeal brushing samples to track disease progression.

Key Insights and Ideas

  • The "Matchmaker" Scaffold: LINC00930 doesn't act alone. It serves as a physical bridge (scaffold) between two epigenetic modifiers: RBBP5 (which methylates histones) and GCN5 (which acetylates them).
  • Epigenetic Overdrive: This lncRNA-protein complex specifically targets the promoter of PFKFB3, a key regulator of glycolysis. By increasing H3K4 trimethylation and H3K9 acetylation, LINC00930 "unlocks" the PFKFB3 gene, cranking up the cell's metabolic engine.
  • Linking Eating to Dividing: The study reveals a direct link between metabolism and the cell cycle. The PFKFB3 pathway increases levels of F-2,6-BP, which triggers the degradation of p27, a protein that normally acts as a "brake" on cell division.
  • A Progression Marker: LINC00930 levels aren't just high in tumors; they increase step-by-step as healthy tissue transforms into precancerous lesions and finally into full-blown NPC.

Key Results

  • Clinical Correlation: High LINC00930 expression was a strong independent predictor of poor prognosis, correlating with lymphatic invasion and advanced TNM stages (Hazard Ratio ~2.1-2.8).
  • Metabolic Impact: Knocking down LINC00930 significantly reduced glycolytic flux, lowering levels of 3-phosphoglycerate, pyruvate, and lactate.
  • Therapeutic Synergy: In PDX models, combining Antisense Oligonucleotides (ASOs) targeting LINC00930 with standard radiotherapy led to dramatic tumor regression compared to radiotherapy alone.
  • Structural Precision: The authors pinpointed the exact amino acid residues (e.g., W279 in RBBP5 and N291 in GCN5) required for the lncRNA to bind its protein partners, providing a blueprint for future small-molecule inhibitors.

Limitations and Future Work

While the results are promising, the authors acknowledge a few hurdles:

  • Delivery Challenges: While ASOs worked well in mouse models, delivering these large molecules effectively and safely to human nasopharyngeal tissues remains a significant pharmacological challenge.
  • Upstream Triggers: The study focuses on what LINC00930 does, but the question of why it becomes overexpressed in NPC in the first place (e.g., specific transcription factors or viral triggers like EBV) remains open for investigation.
  • Broader Application: It is currently unknown if this LINC00930/PFKFB3 axis is a unique feature of NPC or a common metabolic driver across other squamous cell carcinomas.

Summary updated

Abstract

Collectively, LINC00930 is mechanistically, functionally and clinically oncogenic in NPC. Targeting LINC00930 and its pathway may be meaningful for treating patients with NPC.
BibTeX
@article{he2022long,
  author = {Baoyu He and Hongli Pan and Fengque Zheng and Saiqiong Chen and Qingli Bie and Jinghe Cao and Rou Zhao and Jing Liang and Li Wei and Jianchao Zeng and Hui Li and Xing Cui and Yixuan Ding and Chao Wei and Tiantian Xiang and Yuhe Cheng and Gui Qiu and Shishun Huang and Li-Bo Tang and Jiansheng Chang and Delan Luo and Jie Yang and Bin Zhang},
  title = {{Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2022},
  doi = {10.1186/s13046-022-02282-9},
}
Figure